Home > Result Summaries: Compounds > darotropium bromide Result Summaries: darotropium bromide GSKStudy ID Phase Title Summary (Download) 103471 phase 1 A randomised, double blind, placebo-controlled, double dummy, five-way cross over dose-escalation study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 (20-500ug via DPI), and , tiotropium bromide (18ug via DPI) in healthy male subjects (0 citation(s)) 105331 phase 1 A single-centre, randomised, double-blind placebo-controlled, dose-ascending, parallel-group study to evaluate the safety, tolerability, extra-pulmonary pharmacodynamics and systemic and urinary pharmacokinetics of GSK233705 administered twice daily for 14 days in healthy male subjects (0 citation(s)) 112016 phase 1 Phase I study of GSK233705- A randomised, double blind, placebo-controlled, 2-parts study to investigate the safety, tolerability, and pharmacokinetics of single and repeat inhaled doses of GSK233705 from a novel dry powder device in healthy Japanese male subjects - (1 citation(s)) 112146 phase 1 A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy Japanese subjects (0 citation(s)) AC2103473 phase 1 A randomised, double blind, placebo-controlled, double dummy, 4-way cross-over, dose ascending study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single inhaled doses of GSK233705 and tiotropium bromide (18µg) via DPI in COPD patients (0 citation(s)) AC2105333 phase 2 A Randomised, Double-Blind, Placebo-Controlled, Dose Ascending, 3 Period Crossover Study To Examine The Safety, Tolerability, Pharmacodynamics And Pharmacokinetics Of Repeat Inhaled Doses Of GSK233705B In COPD Subjects. (0 citation(s)) AC2106213 phase 1 A single-centre, open-label, sequential ascending cross over study to examine safety, tolerability, pharmacodynamics and pharmacokinetics of ascending single doses, nominally 10, 30, 70 and 110µg intravenous doses and a single 250µg oral dose of GSK233705 in healthy volunteers. (1 citation(s)) AC2106956 phase 2 See Detailed Description (1 citation(s)) AC2108378 phase 2 A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days. (1 citation(s)) AC2108380 phase 1 See Detailed Description (1 citation(s)) AC2110664 phase 2 Dose-Ranging Study for GSK233705B Delivered Once Daily in Subjects with COPD (0 citation(s)) DB1111509 phase 1 A single centre, randomised, placebo-controlled, four-way cross over study to assess the safety, tolerability, pharmacodynamics and pharmacokinetics of single inhaled doses of GSK233705 and GW642444 as monotherapies and in combination in healthy subjects. (1 citation(s))
